XPhyto Therapeutics Debuts on CSE Under Ticker XPHY

After about two years of building relationships with exceptional partners and positioning itself in Canada and Europe, XPhyto Therapeutics (CSE: XPHY) was ready to become a public company. That happened Tuesday morning, with trading beginning on the Canadian Securities Exchange, checking off one more box on management’s list of accomplishments.

Click here to receive an investor deck and corporate updates

The company was founded in 2017 to pursue the next wave of business opportunities in cannabis, such as medical applications, proprietary formulas and emerging European markets. More precisely, XPhyto, through its wholly-owned subsidiaries, is developing a testing, manufacturing, and research business in Canada, as well as a cultivation, import, manufacturing, and distribution business in Germany.

To that end, the parent company has several subsidiaries, including XPhyto Labs in Canada and Bunker Pflanzenextrakte GmbH in Germany.

Jump Start on Canadian Expertise 

Thanks in large part to XPHY Director Dr. Raimar Löbenberg, XPhyto has two, separate 5-year agreements with the University of Alberta’s Faculty of Pharmacy and Pharmaceutical Sciences. Dr. Löbenberg founded the Drug Development and Innovative Centre at the university and is now sharing his wealth of experience and impressive resources with XPhyto. In exchange for all he provided, Dr. Löbenberg is now one of XPHY’s largest shareholders.

XPhyto is immediately in a position to be a leading player in cannabis science in Canada, owing to UofA already being considered an authority. Management made a savvy decision to go the collaborative route in Canada to jump start operations, which saved tens of millions of dollars in capex to build the type of facilities at its disposal now, without mentioning the scientists and staff at UofA.

Per the one agreement, the Faculty of Pharmacy and Pharmaceutical Sciences will manufacture cannabis-based extracts and isolates in its ISO certified clean room for XPhyto for the purposes of research and clinical trials.

According to the other agreement, the university and XPhyto will work together to co-develop a commercial grade analytical lab at UoA for the purpose of testing cannabis and other plant-based medicines. XPhyto has fully funded the development and construction of the analytical testing facility.

Click here to receive an investor deck and corporate updates

First Mover in Germany

Late in July, XPhyto’s Bunker announced that it received a licence for cannabis cultivation and extraction for scientific purposes in Germany, one of the first licenses of its type in the country.

Bunker’s name is quite appropriate given that it has a long-term lease on a former avionics station and nuclear bunker in Bavaria, previously used by the German Bundeswehr Tornado fighter bomber squadron. The nearly 11,000 square-foot facility (with room to expand) is located nearby Munich West airport.

The bunker was built to withstand a nuclear disaster, including radiation-proof doors, thick concrete double walls, back-up power, air filtration and a dedicated internal water well. To that end, some of the infrastructure is already in place for a cannabis business and the building certainly is secure.

XPhyto will need to put about $900,000 into a first phase of renovations to the Bunker facility in order to further additional cannabis licenses and opportunities for storage, import/export, manufacturing and other planned operations catering to the European markets.

Big Market Opportunities

XPhyto is a startup that is moving quickly and with focus as it sees opportunities in its home country in cannabis science rather than fighting for share in the congested cultivation space. Arcview Market Research and partner BDS Analytics estimate that the Canadian cannabis market will reach $5.2 billion within five years.

In Germany, the market is still young, but it is one of the fastest growing in the world on a year-over-year basis.  Arcview forecasts Germany’s cannabis market to grow at 77% compounding annual clip to reach $1.6 billion in the next three years. The market is the flattest of playing fields right now with the German health authority holding its first tender process for cultivation licenses late last year.

Click here to receive an investor deck and corporate updates

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.